Jardiance® (empagliflozin): Potential risk of diabetic ketoacidosis

Boehringer Ingelheim would like to inform healthcare professionals of the potential risk of diabetic ketoacidosis (DKA) during treatment with sodium glucose co-transporter 2 (SGLT2) inhibitors, including Jardiance®. Serious and sometimes life-threatening cases of DKA in patients treated with SGLT2 inhibitors have been reported, with the majority of them requiring hospitalization. The presentation of DKA in a number of cases was atypical in that glucose levels were only mildly elevated at less than 11 mmol/L (or 200 mg/dL), while DKA typically occurs at glucose levels greater than 14 mmol/L (or 250 mg/dL). Healthcare professionals are advised to assess the patients, who are taking SGLT2 inhibitors, for ketoacidosis when they present with signs or symptoms of metabolic acidosis in order to prevent delayed diagnosis and patient management.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.